贝瑞基因：全球首款获准应用于临床的三代基因测序平台Sequel®IICNDx获得医疗器械注册证

Core Viewpoint - Berry Genomics announced that its wholly-owned subsidiary, Hangzhou Berry Genomics and Health Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its third-generation sequencer, Sequel® II CNDx, making it the first third-generation sequencing platform approved for clinical use globally [1] Group 1 - The Sequel® II CNDx is the world's first third-generation sequencing platform approved for clinical application [1] - Berry Genomics has achieved full self-production of third-generation sequencing detection reagents and the local deployment of an intelligent report interpretation system [1]